Abstract
Purpose
A more immediate impact for therapeutic approaches of current clinical research efforts is of major interest, which might be obtained by developing a noninvasive radiation dose-escalation strategy, and neutron capture therapy represents one such novel approach. Furthermore, some recent researches on neutron capture therapy have focused on using gadolinium as an alternative or complementary for currently used boron, taking into account several advantages that gadolinium offers. Therefore, in this study, we carried out feasibility evaluation for both single and multiple injections of gadolinium-based MRI contrast agent incorporated in calcium phosphate nanoparticles as neutron capture therapy agent.
Methods
In vivo evaluation was performed on colon carcinoma Col-26 tumor-bearing mice irradiated at nuclear reactor facility of Kyoto University Research Reactor Institute with average neutron fluence of 1.8 × 1012 n/cm2. Antitumor effectivity was evaluated based on tumor growth suppression assessed until 27 days after neutron irradiation, followed by histopathological analysis on tumor slice.
Results
The experimental results showed that the tumor growth of irradiated mice injected beforehand with Gd-DTPA-incorporating calcium phosphate-based nanoparticles was suppressed up to four times higher compared to the non-treated group, supported by the results of histopathological analysis.
Conclusion
The results of antitumor effectivity observed on tumor-bearing mice after neutron irradiation indicated possible effectivity of gadolinium-based neutron capture therapy treatment.
Similar content being viewed by others
References
Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30(6):1259–1267
Barth RF, Coderre JA, Vicente MGH, Blue TE (2005) Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 11:3987–4002
Brugger RM, Shih JA (1989) Evaluation of gadolinium-157 as a neutron capture therapy agent. Strahlenther Onkol 165:153–156
Cerullo N, Bufalino D, Daquino G (2009) Progress in the use of gadolinium for NCT. Appl Radiat Isot 67:S157–S160
Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolski L, Chanana AD (1998) Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys 40(4):829–834
De Stasio G, Casalbore P, Pallini R et al (2001) Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res 61:4272–4277
De Stasio G et al (2005) Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? Neurol Res 27:387–398
Dewi N, Yanagie H, Zhu H et al (2013) Tumor growth suppression by gadolinium–neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent. Biomed Pharmacother 67:451–457
Dorozhkin SV, Epple M (2002) Biological and medical significance of calcium phosphate. Angew Chem Int Ed Engl 41(17):3130–3146
Epple M et al (2010) Application of calcium phosphate nanoparticles in biomedicine. J Mater Chem 20:18–23
Fuwa N, Suzuki M, Sakurai Y et al (2008) Treatment results of boron neutron capture therapy using intra-arterial administration of boron compounds for recurrent head and neck cancer. Br J Radiol 81:749–752
Gerweck LE, Seetharaman K (1996) Cellular pH gradient in tumor versus normal tissue. Cancer Res 56:1194–1198
Goorley T, Nikjoo H (2000) Electron and photon spectra for three gadolinium-based cancer therapy approaches. Radiat Res 154:556–563
Hambley TW, Hait WN (2009) Is anticancer drug development heading in the right direction? Cancer Res 69:1259–1262
Harms AA, Norman GR (1972) The role of internal conversion electrons in gadolinium-exposure neutron imaging. J Appl Phys 43(7):3209–3212
Henriksson R, Capala J, Michanek A et al (2008) Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high dose of boronophenylalanine (BPA). Radiother Oncol 88:183–191
Ichikawa H, Uneme T, Andoh T, Arita Y, Fujimoto T, Suzuki M et al (2014) Gadolinium-loaded chitosan nanoparticles for neutron-capture therapy: influence of micrometric properties of the nanoparticles on tumor-killing effect. Appl Radiat Isot 88:109–113
Joensuu H, Kankaanranta L, Seppälä T et al (2003) Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neurooncol 62:123–134
Kassis AI, Adelstein SJ, Haydock C, Sastry KSR, McElvany KD, Welch MJ (1982) Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res 90:362–373
Kobayashi H, Watanabe R, Choyke PL (2014) Improving conventional enhanced permeability and retention (EPR) effects; What is the appropriate target? Theranostics 4(1):81–89
Le UM, Cui Z (2006) Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm 312:105–112
Locher GL (1936) Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther 36:1–13
Longmire MR, Ogawa M, Choyke PL, Kobayashi H (2011) Biologically optimized nanosized molecules and particles: more than just size. Bioconjug Chem 22:993–1000
Martin RF, D’Cunha G, Pardee M et al (1989) Induction of DNA doublestrand breaks by 157Gd neutron capture. Pigment Cell Res 2:330–332
Masiakowski JT, Horton JL, Peters LJ (1992) Gadolinium neutron capture therapy for brain tumors: a computer study. Med Phys 19:1277–1284
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the anti-tumor agent smancs. Cancer Res 46:6387–6392
Mi P, Kokuryo D, Cabral H, Kumagai M, Nomoto T, Aoki I, Terada Y, Kishimura A, Nishiyama N, Kataoka K (2014) Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors. J Controlled Release 174:63–71
Mi P, Dewi N, Yanagie H, Kokuryo D, Suzuki M, Sakurai Y, Li Y, Aoki I, Ono K, Takahashi H, Cabral H, Nishiyama N, Kataoka K (2015) Hybrid calcium phosphate-polymeric micelles incorporating gadolinium chelates for imaging-guided gadolinium neutron capture tumor therapy. ACS Nano. doi:10.1021/acsnano.5b00532
Rey C, Combes C, Drouet C, Sfihi H, Barroug A (2007) Physico-chmeical properties of nanocrystalline apatites: implications for biominerals and biomaterials. Mater Sci Eng 27:198–205
Ruoslahti E, Sangeeta NB, Michael JS (2010) Targeting of drugs and nanoparticles to tumor. J Cell Biol 188(6):759–768
Shih JL, Brugger RM (1992) Gadolinium as neutron capture therapy agent. Med Phys 19(3):733–744
Tokumitsu H et al (2000) Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. Cancer Lett 150:177–182
Tung M (1998) Calcium phosphates: structure, composition, solubility, and stability. In: Amjad Z (ed) Calcium phosphates in biological and industrial systems. Kluwer Academic Publishers, Boston, pp 1–19
Watanabe T, Ichikawa H, Fukumori Y (2002) Tumor accumulation of gadolinium in lipid-nanoparticles intravenously injected for neutron-capture therapy of cancer. Eur J Pharm Biopharm 54:119–124
Weinmann HJ, Brasch RC, Press WR, Wesbey GE (1984) Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 142:619–624
Yamamoto T, Matsumura A, Nakai K, Shibata Y, Endo K, Sakurai F, Kishi T, Kumada H, Yamamoto K, Torii Y (2004) Current clinical results of the Tsukuba BNCT trial. Appl Radiat Isot 61(5):1089–1093
Yanagie H, Tomita T, Kobayashi H, Fujii Y, Takahashi T, Hasumi K, Nariuchi H, Sekiguchi M (1991) Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model. Br J Cancer 63(4):522–526
Yanagie H, Ogata A, Sugiyama H, Eriguchi M, Takamoto S, Takahashi H (2008) Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 5(4):427–443
Yasui L, Owens K (2012) Necrosis is not induced by gadolinium neutron capture in glioblastoma multiforme cells. Int J Radiat Biol 88:980–990
Yasui L et al (2008) Gadolinium neutron capture in glioblastoma multiforme cells. Int J Radiat Biol 84:1130–1139
Yuan F (1998) Transvascular drug delivery in solid tumors. Semin Radiat Oncol 8:164–175
Funding
This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science and Culture of Japan (Nos. 25670571, and 24390311 to Hironobu Yanagie).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The procedures for tumor implantation and killing of the animals were carried out following the policies of the Animal Ethics Committee of the University of Tokyo and in accordance with the Declaration of Helsinki.
Rights and permissions
About this article
Cite this article
Dewi, N., Mi, P., Yanagie, H. et al. In vivo evaluation of neutron capture therapy effectivity using calcium phosphate-based nanoparticles as Gd-DTPA delivery agent. J Cancer Res Clin Oncol 142, 767–775 (2016). https://doi.org/10.1007/s00432-015-2085-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-2085-0